Health Catalyst's (HCAT) "In-Line" Rating Reiterated at Evercore ISI

Health Catalyst (NASDAQ:HCAT - Get Free Report)'s stock had its "in-line" rating restated by analysts at Evercore ISI in a research report issued to clients and investors on Wednesday, Marketbeat reports. They presently have a $4.00 price target on the stock, down from their prior price target of $6.00. Evercore ISI's target price points to a potential upside of 5.26% from the company's previous close.

HCAT has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a report on Thursday, February 27th. KeyCorp upgraded shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Royal Bank of Canada decreased their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. Piper Sandler reduced their price objective on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group lowered their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $8.73.

Health Catalyst Trading Down 3.3 %

Shares of NASDAQ:HCAT traded down $0.13 during mid-day trading on Wednesday, reaching $3.80. 145,292 shares of the company's stock were exchanged, compared to its average volume of 615,089. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a twelve month low of $3.60 and a twelve month high of $9.24. The firm has a market capitalization of $266.80 million, a price-to-earnings ratio of -2.81 and a beta of 1.43. The business's fifty day moving average price is $4.65 and its 200-day moving average price is $6.50.

Insider Activity

In related news, General Counsel Benjamin Landry sold 13,827 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares in the company, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now directly owns 216,250 shares in the company, valued at $977,450. This represents a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,030 shares of company stock worth $263,269 in the last three months. Corporate insiders own 2.50% of the company's stock.

Institutional Investors Weigh In On Health Catalyst

Hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock valued at $37,055,000 after acquiring an additional 944,631 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after acquiring an additional 861,150 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Health Catalyst by 42.7% during the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock valued at $13,369,000 after buying an additional 565,445 shares during the period. Penn Capital Management Company LLC purchased a new position in shares of Health Catalyst during the 4th quarter worth approximately $3,506,000. Finally, Palogic Value Management L.P. bought a new position in Health Catalyst in the fourth quarter worth $2,262,000. Institutional investors own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.